Sapient Discovery, LLC.
|Title:||President and Chief Scientific Officer|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||Advances in genome sequencing and disease processes have resulted in a glut of potential new drug targets. While high throughput screening (HTS) methods have played some role in easing this bottleneck, HTS is very expensive, has limited scalability, and samples a very small portion of “structural space” -- typically limited to screening the already “over-mined” in-house libraries of drug companies. HTS poses a formidable economic challenge to many smaller companies. Larger pharmaceutical companies, while able to afford high throughput screening, have throughput and queuing issues, causing delays or exclusion of promising targets screening.
Sapient Discovery offers an accelerated, powerful, and proven structure-based approach to accelerating lead discovery and optimization for protein drug targets, termed Genes-to-Leads®. Genes-to-Leads® combines four technologies: X-ray crystallography, Augmented Homology Modeling, StructureBank™ and DynaPharm™ based virtual screening, for rapidly identifying novel and selective small-molecule inhibitor/antagonist leads with 100 fold increase in drug screening efficiency.
Genes-to-Leads® is offered as a stand-alone business solution for smaller biotech or pharma companies. And integration of the proprietary. The technology has delivered novel, selective, multi-scaffold, lead molecules for more than 18 targets.
|Venture is:||Seed Level|